Dymara-Konopka Weronika, Laskowska Marzena, Oleszczuk Jan
Department of Obstetrics and Perinatology, Medical University of Lublin, Poland, 20-950 Lublin, Jaczewskiego 8, Poland.
Curr Pharm Biotechnol. 2018;19(10):786-796. doi: 10.2174/1389201019666180925120109.
Preeclampsia is one of the most serious pregnancy - specific medical conditions of increasing incidence. It remains a major cause of maternal and fetal morbidity and mortality. Although maternal mortality is especially high in developing countries, preeclampsia and its complications are one of the top four causes of maternal deaths even in developed societies. Unfortunately, yet the only effective and definitive treatment of preeclampsia is delivery of the baby and placenta, and its time depends on the disease severity and gestational age. In this review, we report principles of management of preeclampsia in the light of current international recommendations. Suggested failure of the placental development and significant role of angiogenic factors and their receptors in etiology of preeclampsia give the possibility for their future use in diagnosis and risk assessment of the disease and open new chapter of possible solutions also in the field of treatment of this serious pregnancy complication. Introduction of an advanced form of therapy that could safely prolong the duration of pregnancy would be invaluable in the area of preeclampsia management and lowering perinatal complications, especially in women with early-onset severe preeclampsia.
子痫前期是发病率不断上升的最严重的特定妊娠相关病症之一。它仍然是孕产妇和胎儿发病及死亡的主要原因。尽管发展中国家的孕产妇死亡率特别高，但即使在发达社会，子痫前期及其并发症也是孕产妇死亡的四大主要原因之一。不幸的是，子痫前期唯一有效且确切的治疗方法是娩出胎儿和胎盘，而娩出时间取决于疾病严重程度和孕周。在本综述中，我们根据当前国际建议报告子痫前期的管理原则。胎盘发育异常以及血管生成因子及其受体在子痫前期病因中的重要作用，为它们未来用于该疾病的诊断和风险评估提供了可能性，也为解决这一严重妊娠并发症的治疗领域开启了新的篇章。引入一种能够安全延长孕期的先进治疗方法，在子痫前期管理和降低围产期并发症方面将具有不可估量的价值，尤其是对于早发型重度子痫前期患者。
